Dr Korendowych is a Consultant Rheumatologist and Clinical Lead for Rheumatology at the Royal National Hospital for Rheumatic Diseases in Bath. She undertook her medical training at Cambridge and Oxford Universities. She was appointed as a Consultant at the RNHRD in Bath in 2005. She became Clinical Lead for the Rheumatology Unit in 2007 and was appointed as Medical Director of the RNHRD in 2014. Dr Korendowych’s main clinical and research interests are in Psoriatic Arthritis (PsA) and the Autoimmune Connective Tissue Disorders especially Lupus.
Dr Korendowych was awarded an Arthritis Research Campaign Travelling Fellowship to undertake a PhD in Australia in 2001-2003. In 2004 she was awarded her PhD by the University of Bath for ‘An Immunogenetic Study of Psoriatic Arthritis’. She has published widely on PsA and has led national workshops on the clinical assessment of PsA. She is a member of the International Consortium of experts in PsA known as GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis). She is a member and former Steering Group founding member of PAGE (PsA Genetics European Consortium) which facilitates collaborative research across Europe into the Genetics of PsA. She is a founder member of BRIT-PACT (British PsA Consortium). She is a medical advisor for the Psoriasis and Psoriatic Arthritis Alliance. She undertakes Clinical trials in PsA and contributes to a number of non-commercial research programmes at the RNHRD in Bath on outcome measures, genetics, biomarkers and biologics in PsA. She is the National Expert for NICE appraisals for biologics in PsA for the British Society of Rheumatology. In 2007, she established one of the first dedicated PsA biologics clinics in the country which attracts referrals from around the UK. Her main areas of expertise are in biologic therapy, outcome measures and assessment, co-morbidities and the immunogenetics of PsA.
Dr Korendowych also leads the Lupus service at the RNHRD and developed a dedicated Lupus clinic to assess outcome measures and co-morbidities in patients with Lupus. In 2015, Dr Korendowych and her team were recognised as a Lupus Centre of Excellence by Lupus UK.
view this profile
Philip Helliwell is currently Associate Professor in Rheumatology at the University of Leeds, UK, and Honorary Consultant Rheumatologist for the Leeds Teaching Hospitals and Bradford Teaching Hospitals NHS Trust.
Dr Helliwell qualified in Oxford in 1972 and worked initially in London before returning to work in his native Yorkshire in medical physics. After a period working in Australia and New Zealand he returned in 1985 to Leeds to join Prof Verna Wright and to work on psoriatic arthritis and biomechanics.
Dr Helliwell is a member of ASAS (Assessment of Spondyloarthropathy Society) and co-founder and President of the Group for Research and Assessment of Psoriasis and Psoriatic arthritis (GRAPPA). He established and led the CASPAR study for classification of psoriatic arthritis. He has worked with GRAPPA in developing single and composite outcome measures in psoriatic arthritis and completed the first treat to target strategy study (TICOPA) in early psoriatic arthritis.
He is co-founder and co-lead for the Bradford (University) Diploma in Rheumatology and Musculoskeletal Medicine and is an active member of the Bradford and Airedale Musculoskeletal Alliance, a tier 2 service provided to GPs in the designated geographical area.
Dr Helliwell is co-founder of the Leeds foot and ankle studies group and has published widely on foot and ankle problems in inflammatory arthritis including rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. He has contributed to several guidelines on management of foot and ankle problems in the UK.
Dr Helliwell has published over 300 peer reviewed papers. Current and past research in psoriatic arthritis includes treatment paradigms, clinical features and classification of psoriatic arthritis and community based studies of psoriasis and psoriatic arthritis. He has also published on biomechanics of joints, gait assessment and foot disorders in inflammatory and non-inflammatory arthritis, and epidemiology of rheumatic diseases.
view this profile